Lexicon Pharmaceuticals: Diabetes Mellitus trials

The registry lists 23 Diabetes Mellitus studies with Lexicon Pharmaceuticals as lead sponsor. 0 are open to participants now and 20 have results posted.

Phase 1 3Phase 2 6Phase 3 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic PainCompletedNCT04455633Phase 2Results posted
• Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)TerminatedNCT03521934Phase 3Results posted
• Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlTerminatedNCT03386344Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With MetforminCompletedNCT03351478Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyCompletedNCT03332771Phase 3Results posted
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskTerminatedNCT03315143Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic AgentsCompletedNCT03285594Phase 3Results posted
• Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlCompletedNCT03242252Phase 3Results posted
• A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlCompletedNCT03242018Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With MetforminCompletedNCT03066830Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of MetforminCompletedNCT02926950Phase 3Results posted
• Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic TherapyCompletedNCT02926937Phase 3Results posted
• A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy AloneCompletedNCT02531035Phase 3Results posted
• Dose-ranging Study in Patients With Type 1 Diabetes MellitusCompletedNCT02459899Phase 2Results posted
• Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCompletedNCT02421510Phase 3Results posted
• Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyCompletedNCT02384941Phase 3Results posted
• Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1CCompletedNCT02383940Phase 2Results posted
• Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes MellitusCompletedNCT01742208Phase 2Results posted
• Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on MetforminCompletedNCT01376557Phase 2Results posted
• Study of LX4211 in Subjects With Type 2 Diabetes MellitusCompletedNCT00962065Phase 2Results posted
• Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal ImpairmentCompletedNCT01555008Phase 1
• A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 DiabeticsCompletedNCT01441232Phase 1
• Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes MellitusCompletedNCT01188863Phase 1